

New investors join BIOXIS Pharmaceuticals to accelerate development of MTI12, the First Monophasic Tissular inductor

Lyon & Beijing - September 19, 2016: BIOXIS Pharmaceuticals, the developer of MTI12, the world's first Monophasic Tissular inductor announced today the signing of an agreement with JUVAMED for its development in China.

Under this agreement, BIOXIS Pharmaceuticals and JUVAMED will cooperate to obtain Chinese Food and Drug Administration (CFDA) approval for the two dermal filler technologies developed by Bioxis; MTI12, based on pharmaceutical grade chitosan and CYTOSIAL, based on crosslinked hyaluronic acid.

"In Juvamed we have found a partner with intimate knowledge of the Chinese market for aesthetic dermatology, essential for the acceleration of our development in this key territory. A key element of our partnership is that Juvamed shares our vision and strategy of establishing MTI12 technology as the new reference of the global dermal filler market." said Frédéric Bertaina, CEO of BIOXIS Pharmaceuticals.

In addition, Juvamed together with two European family offices, invested a total of EUR 2.5 million to enable BIOXIS to continue to develop its highly promising technologies and to hire new talent.

Bioxis worked closely with Business France (the Agency supporting the international development of the French economy) to identify and meet with potential Chinese partners (including physicians, distributors and investors such as Juvamed).

About BIOXIS Pharmaceuticals

Bioxis Pharmaceuticals (formerly Cytosial Biomedic) specializes in the discovery, development, production, and commercialization of innovative products in regenerative medicine, notably MTI12, the world's first Monophasic Tissular Inductor based on pharmaceutical grade chitosan. Founded in 2010 by Frédéric Bertaina, Bioxis Pharmaceuticals, which is certified ISO 13485, has 10 employees, including senior management with extensive experience garnered at major players in aesthetic dermatology.

The company has received the support of Medicen, the life sciences cluster of the Paris Region (EIP label) as well as the financial support of BPI France (French public investment bank).



About JUVAMED Group

JUVAMED group is the leading actor in innovative medical aesthetic technology in China with annual sales of over US\$300 million.

As well as distributing medical aesthetic devices, Juvamed has the largest network of medical aesthetic clinics and hospitals, and aesthetic centers in China. The network, comprising more than 30 clinics and over 2000 beauty SPAs with 3 brands: Beauty Farm, PalaiSPA and ESPA, offers the full range of aesthetic services from plastic surgery to laser-based aesthetic treatments.

Legal advisors to Bioxis:

Dentons: Julien Le Guyader, Guillaume Panuel, David Li

Sebban & Partenaires: David Sebban

Financial advisor to Bioxis:

Chausson Finance: Katherine Wong Selz

Financial advisor to Juvamed:

Gold Pier Capital: Joshua Hu

